Source: Annual Congress 2003 - The challenge of community acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. de Roux, M. A. Marcos, J. Puig de la Bellacasa, A. Rano, J. Mensa, S. Ewig, A. Torres (Barcelona, Spain; Bochum, Germany). Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP). Eur Respir J 2003; 22: Suppl. 45, 3412

Member's Comments

No comment yet.

Related content which might interest you: Differences in prognostic factors and outcome in community-acquired pneumonias (CAP) caused by viral pathogens (VP) or streptococcus pneumoniae (SP) Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005 S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistance Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006 Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004 Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Genetic diversity of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolates from community acquired pneumonia (CAP) in china Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 Impact of telithromycin (T), azithromycin (A) and cefuroxime axetil (C) on the carriage of resistant streptococcus pneumoniae (Sp) in pts with acute exacerbation of chronic bronchitis (AECB) Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Streptococcus pneumoniae resistance pattern and its clinical implications Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006 Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 Definition of severity and the reasons for hospitalization (RH) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort. Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015